I
mmunosuppressive drugs play an important role in the treatment of inflammatory bowel diseases (IBDs) in pediatric patients. Thiopurine analogs (azathioprine and 6-mercaptopurine) are traditionally the first-line agents. However, 20% to 50% of patients treated with these immunosuppressive drugs will either develop adverse events or unresponsiveness. [1] [2] [3] Methotrexate (MTX), an immunosuppressive drug frequently used in rheumatology, has been studied in the past few years for IBD treatment. It has shown its efficacy in pediatric Crohn's disease (CD) and is gaining popularity over thiopurines as a first-line treatment. [2] [3] [4] [5] [6] [7] Current ECCO/ESPGHAN Guidelines recommend the use of MTX for CD either as a primary maintenance therapy or if thiopurine treatment fails. 8 Studies on MTX efficacy in ulcerative colitis (UC) and IBD unclassified in adults have shown inconsistent results. 9, 10 In children, one retrospective study found a statistically nonsignificant lower remission rate in UC compared with CD. 7 Adverse events associated with MTX have been noted in rheumatology patients and in patients with IBD. Fortunately, serious adverse events, including hepatotoxicity, pulmonary toxicity, and bone marrow suppression are rare. However, gastrointestinal symptoms, such as abdominal pain, nausea, and vomiting, are frequent side effects and can be very incapacitating.
In addition to gastrointestinal side effects, psychological side effects have been observed and studied in rheumatology as well as behavioral adverse effects. Psychological side effects are defined as anticipatory symptoms (symptoms occurring before MTX intake) and associative symptoms (symptoms occurring when thinking of MTX). Behavioral side effects consist of restlessness, crying, and irritability when taking MTX or refusal to take MTX.
A Methotrexate Intolerance Severity Score (MISS) has been developed in rheumatology to identify patients with MTX Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.ibdjournal.org).
intolerance. 11 MTX intolerance is defined as anticipatory or associative gastrointestinal symptoms, gastrointestinal symptoms occurring after MTX administration, and behavioral symptoms occurring during MTX administration that could lead to treatment discontinuation. Using the MISS questionnaire, Bulatovic et al 11 showed that 50.5% of children with juvenile idiopathic arthritis were intolerant to MTX. In children with IBD, the prevalence of MTX intolerance has never been evaluated.
The aim of this study was to determine the prevalence of MTX intolerance in pediatric IBD using the MISS questionnaire and to identify risk factors for developing MTX intolerance.
MATERIALS AND METHODS

Study Design and Patient Recruitment
From May 2014 to July 2016, all patients who had initiated a treatment with MTX between 2004 and 2016 in the pediatric IBD clinic of Sainte Justine Hospital were contacted directly in the clinic or by telephone and those who were still receiving MTX were invited to fill out the MISS questionnaire. The inclusion criteria were MTX received for IBD (CD, UC, and IBD unclassified), age at initiation of MTX ,18 years, and duration of MTX treatment of at least 3 months.
Description of the MISS Questionnaire
The MISS questionnaire developed by Bulatovic et al 11 consists of 4 domains (abdominal pain, nausea, vomiting, and behavioral symptoms). Each domain is detailed into 2 to 4 items according to the timing of symptoms: from several hours to 1 day before taking MTX (anticipatory), when thinking of MTX (associative), or after taking MTX. For each item the severity of symptoms is ranked from 0 (no complaint) to 3 (severe complaint). The total score ranges from 0 to 36.
For the purpose of this study, 2 versions of the MISS questionnaire were distributed per family: one for self-evaluation of symptoms by patients aged 10 years and older and another for evaluation of symptoms by the parents. The questionnaires were self-administered and assisted, if necessary, by a research assistant who was blinded to the patient's medical history. For patients who were younger than 10 years or unable to answer, only the parent's questionnaire was used; for patients between 10 and 18 years, questionnaires from both the patient and parent were collected; for patients older than 18 years, the patient's questionnaire was collected and the parent's questionnaire was optional. Among the 30 patients for whom the child's and parent's questionnaire were both available, there was a significant correlation between children's and parents' answers (Pearson correlation coefficient ¼ 0.86 [P , 0.0001]). Thus, parents' MISS questionnaire was used as a proxy for child's response if no questionnaire was available from the child.
Data Collection
Data pertaining to baseline clinical characteristics, description of MTX treatment, and adverse events were retrieved retrospectively from the medical charts. Adult patients who were no longer followed in the pediatric IBD clinic were contacted by telephone and questioned on their current treatment. The researchers who retrieved the data were blinded to the patient's answers to the MISS questionnaire.
Outcome
The primary outcome was "Intolerance to MTX," defined according to Bulatovic et al 11 as a total score on the MISS questionnaire of $6 with at least 1 point on anticipatory and/or associative and/or behavioral symptoms.
Translation of the MISS Questionnaire
The items of the MISS questionnaire were translated into French by 2 bilingual researchers using a translation-reverse translation approach (see Figures 
Statistical Analysis
Baseline characteristics of patients who had developed MTX intolerance and those who had not were compared using Chi-square tests for qualitative data and Student's t tests for quantitative data. Variables associated with MTX intolerance with a P , 0.15 were included in a multivariate logistic regression model, using a stepwise selection of variables. Interactions between variables were tested. Goodness of fit of the final model was tested using a Hosmer and Lemeshow test. 12 A final value of P , 0.05 was considered significant.
All analyses were performed using SAS 9.2 statistical package (SAS Institute, Cary, NC).
ETHICAL CONSIDERATIONS
The study protocol was approved by Sainte Justine Hospital Institutional Review Board. All patients and parents of minors gave their written consent for participation in the study.
RESULTS
Study Population
Based on the Sainte Justine IBD clinic database, 245 patients received MTX between 2004 and 2016: 110 discontinued MTX, 26 were lost to follow-up, 7 declined the study, and 102 patients who were actively on MTX were included.
Description of MTX Treatment
Among the 102 patients (59% males), 74% had CD and 26% had UC or IBD unclassified. Median age at initiation of MTX was 15.0 years (interquartile range [IQR]: 12.7-16.7). The median initial dose of MTX was 14.3 mg$m 22 $wk 21 (IQR: 11.0-15.8). Initial route of administration was subcutaneous in 75% and oral in 25% of patients. Thirteen percent of the study cohort had already been treated in the past with MTX. Folic acid supplements were prescribed from baseline in 94% of patients and prophylactic antiemetics (versus on demand) in 62%. The antiemetics prescribed were (several possible) ondansetron (n ¼ 56 patients), metoclopramide (n ¼ 4), dimenhydrinate (n ¼ 3), and domperidone (n ¼ 2).
Results of the MISS Questionnaire
Among the 102 patients, questionnaires were obtained from child only (n ¼ 38), parent only (n ¼ 27), or both (n ¼ 37). The median duration of MTX treatment at completion of the MISS questionnaire was 9.8 months (IQR: 5.1-29.0).
Thirty-two patients (31%) fulfilled the criteria for MTX intolerance based on the symptoms reported. Results from the questionnaires are detailed in Table 1 . Considering the whole study population, abdominal pain was noted in 28 patients (27%), nausea in 56 (55%), vomiting in 21 (21%), and behavioral symptoms in 37 (36%). Gastrointestinal symptoms occurred after taking MTX in 60 patients (59%), before taking MTX (anticipatory symptoms) in 36 patients (35%), and when thinking of MTX (associative symptoms) in 35 patients (34%). Mean MISS score was 1.5 6 1.6 in the "MTX-tolerant" group and 9.8 6 3.2 in the "MTX-intolerant" group.
Predictors of MTX Intolerance
Clinical characteristics by MTX tolerance status are indicated in Table 2 (see Table, 
MTX Intolerance and Disease Activity
To analyze if the gastrointestinal symptoms reported were medication related and not disease related or due to a lack of treatment efficacy, we looked for an association between each item of the MISS questionnaire and disease activity based on the most recent PGA (less than 3 months before MISS). The only symptom associated with active disease was nausea after taking MTX (OR 1.71 [95% CI, 1.06-2.77], P ¼ 0.03) (see Table, Supplementary Digital Content 4, http://links.lww.com/IBD/B436, for detail). There was no association between anticipatory or associative symptoms and disease activity.
Adverse Events
Based on chart review (independently from patient's responses to MISS questionnaire), the first medical note containing the word "nausea" in the chart was recorded after a median 5.1 months (IQR 2.0-51.7) of treatment in 17 (24%) patients from the "MTX-tolerant" group and after a median 3.8 months (IQR 0.6-31.8) in 16 (50%) patients from the "MTX-intolerant" group.
Patients who had received ondansetron secondarily (versus prophylactic) were significantly more likely to be in the "MTX intolerant" group (P ¼ 0.001). Anxiolytics were prescribed secondarily in 1 patient and antiacids in 3 patients.
Nineteen patients (19%) had at least one episode of lymphopenia ,1.0 · 10 3 /mm 3 on the regular follow-up tests, 13 (19%) in the MTX-tolerant group, and 6 (19%) in the MTXintolerant group. Only one patient had hepatotoxicity, which is defined as an elevation of the alanine aminotransferase level above 2 times the upper limit of normal. The other adverse events noted in the chart and delay-of-onset are shown in Table 3 .
Intolerance to MTX Based on Physician's Assessment
Physicians from the IBD clinic were asked to evaluate whether or not their patient was intolerant to MTX without access to the patient's MISS questionnaire. The physician was instructed to score "intolerant to MTX" if the patient answered the following criteria: "presence of gastrointestinal symptoms before and after MTX intake, a persistent nature of these symptoms, and/or a negative effect of these symptoms in the days after MTX intake." 11 Data on physician's evaluation was available for 33 patients: 24 where deemed tolerant to MTX and 9 intolerant. Patient's and physician's answers were not statistically associated (P ¼ 0.12): physicians tended to underestimate the diagnosis of MTX intolerance.
DISCUSSION
Although nausea and vomiting after administration of MTX are frequently noted in adult and pediatric studies, 3, 4, 13 anticipatory and associative symptoms are much more challenging to identify and standardized tools to measure them were lacking until the MISS was developed. Although this score was validated in rheumatology, we were able to apply it to pediatric patients with IBD and found a prevalence of MTX intolerance of 31%. This finding is much lower than the prevalence of MTX intolerance reported in juvenile idiopathic arthritis (50.5%) 11 but higher than the prevalence found in a study on rheumatoid arthritis and psoriatic arthritis (11%) in which both adult and pediatric patients were included. 14 In the latter study, MTX intolerance was less frequent in adults, explaining the lower overall prevalence of MTX intolerance. This difference suggests that children have a stronger classic conditioning response to MTX, meaning that they have a tendency to develop anticipatory and associative symptoms in contrast with adults. 11, 14, 15 A potential limitation of using the MISS in IBD is that gastrointestinal symptoms could reflect disease activity and drug-related side effects. We did not have PCDAI, fecal calprotectin, or data on mucosal healing for all the patients. We chose to report PGA as it had been prospectively assessed by the treating physician for each patient and because previous studies have shown a significant correlation between PGA and PCDAI. 16 However, there are 2 reasons to think that the questionnaire was effectively specific of drug-related side effects and not merely ongoing disease activity-first of all, the prevalence of gastrointestinal symptoms in our patients with IBD was similar or lower to the prevalence of gastrointestinal symptoms in rheumatology patients 11 showing that the gastrointestinal side effects of MTX seem independent from the site of disease: digestive tract versus joints. Second, although disease activity according to PGA was independently associated with MTX intolerance, we showed that the only symptom of the MISS that was associated with active disease was nausea after receiving MTX. We conclude that symptoms occurring after administration of MTX could be due either to drug-related symptoms or to disease activity; whereas, anticipatory or associative symptoms are highly suspicious of drug-related intolerance independently from disease activity.
The risk factors for MTX intolerance that we identified are female sex and a higher dose of MTX (independently from disease activity). Female sex is a well-known risk factor for anticipatory nausea and vomiting related to chemotherapy. 17 As for doses, Bulatovic et al 11 had already described a trend toward increased MTX intolerance with higher doses of MTX.
Anticipatory and associative symptoms to a drug are generated by Pavlovian classic conditioning, which means that the patient was exposed to an unconditioned stimulus (e.g., MTX) and experienced an unconditioned response (e.g., nausea or vomiting). At that time, several conditioned stimuli may have been present (e.g., the yellow color of the MTX fluid). After a certain time of conditioning (e.g., patient has repetitive nausea after each MTX administration), the patient develops conditioned response (e.g., nausea) to the conditioned stimulus (e.g., the color yellow). 11, 17 A recent study by Molassiotis et al 18 showed that predictors of chemotherapy-related anticipatory nausea are prechemotherapy anxiety and history of chemotherapy-induced nausea and vomiting. Anticipatory nausea and vomiting are typically unresponsive to antiemetic medication. 19 Current perspectives for treating anticipatory nausea and vomiting are psychotherapies such as desensitization and hypnosis or benzodiazepines, but results are unconclusive. 17 The most effective treatment of conditioned responses is to prevent triggering of the conditioning by preventing the unconditioned response: in the case of MTX intolerance, by preventing rigorous nausea and vomiting after MTX administration using antiemetics from baseline. Ondansetron has been shown to be effective in this indication. 20 In our study, the effect of prophylactic antiemetics was not significant, whereas, secondary prescription of ondansetron was strongly associated with MTX intolerance. In this retrospective study, compliance with prophylactic antiemetics could not be ascertained which might explain the absence of efficacy.
In keeping with these observations, we have shifted our practice in the IBD clinic to a more systematic prescription of prophylactic ondansetron administered before and after doses of MTX at least for the first 3 months of treatment followed by ondemand administration of ondansetron. Based on our results, we suggest that prevention of nausea should be paramount in patients at risk for MTX intolerance, in particular, female patients and patients receiving higher doses of MTX.
As Bulatovic et al 11, 14 pointed out in their articles on MTX intolerance in rheumatoid arthritis and psoriatic arthritis as well as in juvenile idiopathic arthritis, anticipatory and associative symptoms are not clinically evident, and it can be hard for physicians to assess the presence of these symptoms, thus the importance of the MISS questionnaire. By implementing routine screening of MTX intolerance using the MISS shortly after initiation of MTX, it might be possible to detect the onset of anticipatory and associative symptoms during the period of conditioning and treat them before they become too severe, leading to discontinuation of treatment. We do not believe that the MISS will induce Pavlovian nausea or vomiting. This is supported by the recent publication by Van Dijkhuizen et al 21 who studied prospectively the development of MTX intolerance during the first year of treatment in juvenile idiopathic arthritis using the MISS. In their study, most patients developed MTX intolerance between 6 and 12 months of treatment, and the prevalence of MTX intolerance at 1 year was not higher than the one previously reported by their team (41.5% versus 50.5%), 11, 21 meaning regular use of the MISS is possible and does not induce MTX intolerance.
CONCLUSION
MTX is frequently used in the treatment of pediatric IBD, but MTX intolerance may be incapacitating. With the MISS questionnaire, we were able to identify anticipatory and associative gastrointestinal and behavioral symptoms associated with 
